Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 179.52 USD 1.11% Market Closed
Market Cap: 26.3B USD

Operating Margin
Biogen Inc

28.5%
Current
27%
Average
-3.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
28.5%
=
Operating Profit
2.9B
/
Revenue
10.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Biogen Inc
NASDAQ:BIIB
26.3B USD
29%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.4B USD
33%
US
Amgen Inc
NASDAQ:AMGN
171.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD
28%
AU
CSL Ltd
ASX:CSL
86.6B AUD
26%
NL
argenx SE
XBRU:ARGX
46.7B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD
8%
No Stocks Found

Biogen Inc
Glance View

Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.

BIIB Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
28.5%
=
Operating Profit
2.9B
/
Revenue
10.1B
What is the Operating Margin of Biogen Inc?

Based on Biogen Inc's most recent financial statements, the company has Operating Margin of 28.5%.

Back to Top